Overview
- Carnegie Imaging for Women, a Mount Sinai–affiliated center with three Manhattan locations, is the first in New York City to deploy the FDA-approved BrightHeart software at scale.
- An Obstetrics & Gynecology study led by Mount Sinai West reported detection of ultrasound findings suspicious for major congenital heart defects exceeding 97%, with an 18% reduction in reading time and a 19% gain in confidence.
- The randomized reader study analyzed 200 deidentified second-trimester exams from 11 medical centers across two countries, interpreted by 14 specialists with and without AI assistance.
- Study authors say the tool could help standardize prenatal cardiac screening by offering near–expert-level review in settings that lack fetal heart specialists.
- The research was funded by BrightHeart, and the team urges further evaluation of workflow integration, generalizability, and downstream clinical impacts.